ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
10.96
-1.55 (-12.39%)
At close: Apr 6, 2026, 4:00 PM EDT
11.36
+0.40 (3.65%)
Pre-market: Apr 7, 2026, 5:34 AM EDT
ProMIS Neurosciences Employees
As of December 31, 2025, ProMIS Neurosciences had 11 total employees, including 10 full-time and 1 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$3,610,832
Market Cap
98.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 11 | 3 | 37.50% | 10 | 1 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2021 | 6 | 5 | 500.00% | 5 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Inovio Pharmaceuticals | 112 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| Vivani Medical | 42 |
| Aardvark Therapeutics | 40 |
| LeonaBio | 26 |
| TuHURA Biosciences | 22 |
PMN News
- 13 days ago - ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 20 days ago - ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire